Wednesday, February 01, 2017 7:55:47 AM
We also have 121 on a fast track and the change in trial structure by MACK may accelerate that process.
Once the $1.54 gets paid constant with a price of $3.11 you will have a three year call on four drugs..I include 151 which I think the company would like to keep looking at..for three years. I have a new CEO who according to my sources is top drawer. There are the naysayers who portray the clinical portfolio as stale. I think the fellow that drove us into the ground..Mulroy..was the wrong guy and
the Board was culpable.
There has been no sales in the top four institutional owners. I expect the shareholder vote to go for the deal. If 398 gets to $200 Million with off label use Ipsen made a great deal.
Recent MACK News
- Merrimack Receives $225 Million Milestone Payment from Ipsen • Business Wire • 03/27/2024 08:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:42:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:39:03 PM
- Merrimack Reports Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:15:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 03/07/2024 05:29:51 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 09:44:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:20:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/13/2024 09:26:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:22:56 PM
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • Business Wire • 02/13/2024 09:18:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 11:59:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 10:09:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:30:25 PM
- Merrimack Reports Third Quarter 2023 Financial Results • Business Wire • 11/02/2023 08:30:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 08/14/2023 08:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2023 08:06:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:36:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/03/2023 08:31:02 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM